Intestinal and blood-brain drug transport: Beyond involvement of a single transport function

Drug Discovery Today: Technologies

Volumn 1, Issue 4, 2004, Pages 417-422

  Lennernäs, Hans ^a   Lundgren, Ebba ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; ATENOLOL; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CEFALEXIN; CIMETIDINE; DESIPRAMINE; ENALAPRIL; ENALAPRILAT; FEXOFENADINE; FLUINDOSTATIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; KETOPROFEN; LEVODOPA; LISINOPRIL; MELAGATRAN; METOPROLOL; METOPROLOL TARTRATE; NAPROXEN; PHENAZONE; PIROXICAM; PROPRANOLOL; TERBUTALINE; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VERAPAMIL;

ACCURACY; ARTICLE; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; PREDICTION;

EID: 13244292177     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2004.11.010     Document Type: Review

References (26)

1. H. van De Waterbeemd et al. Property-based design: Optimization of drug absorption and pharmacokinetics J. Med. Chem. 44 2001 1313-1333
2. H. Lennernas Human jejunal effective permeability and its correlation with preclinical drug absorption models J. Pharm. Pharmacol. 49 1997 627-638
3. H. Lennernas Intestinal drug absorption and bioavailability: Beyond involvement of single transport function J. Pharm. Pharmacol. 55 2003 429-433
4. S. Lundquist et al. Prediction of drug transport through the blood-brain barrier in vivo: A comparison between two in vitro cell models Pharm. Res. 19 2002 976-981
5. J.K. Kelder et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 16 1999 1514-1519
6. M. Rowland et al. Physiologically based pharmacokinetics in drug development and regulatory science: A workshop report (Georgetown University, Washington, DC, 29-30 May 2002) AAPS PharmSci. 6 2004 E6
7. H. Lennernas et al. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo Int. J. Pharm. 127 1996 103-107
8. D. Sun et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs Pharm. Res. 19 2002 1400-1416
9. H. Lennernas Human intestinal permeability J. Pharm. Sci. 87 1998 403-410
10. W.L. Chiou et al. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans Int. J. Clin. Pharmacol. Ther. 39 2001 93-101
11. L.X. Yu et al. Biopharmaceutics classification system: The scientific basis for biowaiver extensions Pharm. Res. 19 2002 921-925
12. C. Tannergren et al. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine Clin. Pharmacol. Ther. 74 2003 423-436
13. N. Petri et al. Transport characteristics of fexofenadine in the Caco-2 cell model Pharm. Res. 21 2004 1398-1404
14. N. Petri H. Lennernas In vivo permeability studies in the gastrointestinal tract of humans In Drug Bioavailability (H. van de Waterbeemd, ed.) 2003 Wiley-Vch Verlag GmbH & Co 155-188
15. B. Steffansen et al. Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption Eur. J. Pharm. Sci. 21 2004 3-16
16. P. Ettmayer et al. Lessons learned from marketed and investigational prodrugs J. Med. Chem. 47 2004 2393-2404
17. H. Han et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter Pharm. Res. 15 1998 1154-1159
18. P.W. Swaan et al. Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis Receptors Channels 6 1998 189-200
19. H. Lennernas et al. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: Experience from a regional perfusion technique Eur. J. Pharm. Sci. 15 2002 271-277
20. S. Winiwarter et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach J. Med. Chem. 41 1998 4939-4949
21. B.I. Eriksson et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Melagatran for thrombin inhibition in orthopaedic surgery Thromb. Haemost. 87 2002 231-237
22. R. Sandstrom et al. Jejunal absorption and metabolism of R/S-verapamil in humans Pharm. Res. 15 1998 856-862
23. D.E. Clark In silico prediction of blood-brain barrier permeation Drug Discov. Today 8 2003 927-933
24. S. Lundquist M. Renftel The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry - background and current status in the drug discovery process Vascul. Pharmacol. 38 2002 355-364
25. F. Faassen et al. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs Int. J. Pharm. 16 2003 113-122
26. V. Berezowski et al. Transport screening of drug cocktails through an in vitro blood-brain barrier: Is it a good strategy for increasing the throughput of the discovery pipeline? Pharm. Res. 21 2004 756-760